Senores Pharmaceuticals Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Senores Pharmaceuticals Ltd. on BSE

Load latest

Senores Pharmaceuticals Ltd.

15 May 2025

612.45

0.16%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Senores Pharmaceuticals Limited has informed the Exchange regarding the media release in relation to the Audited Standalone and Consolidated financial results of the Company for the quarter and financial year ended March 31, 2025.

pdf

Senores Pharmaceuticals Ltd.

15 May 2025

612.45

0.16%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Intimation Regarding Changes In The Senior Management Personnel ('SMP') Of …

BSE India

Senores Pharmaceuticals Limited has informed the Exchange regarding changes in the Senior Management Personnel ("SMP") of the Company.

pdf

Senores Pharmaceuticals Ltd.

15 May 2025

612.45

0.16%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Appointment Of Secretarial Auditor For A Period Of Five (5) …

BSE India

Senores Pharmaceuticals Limited has informed the Exchange regarding appointment of Secretarial Auditor for a period of five (5) consecutive year from FY 2025-26 to FY 2029-30.

pdf

Senores Pharmaceuticals Ltd.

15 May 2025

612.45

0.16%

Board Meeting

Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.

pdf

Senores Pharmaceuticals Ltd.

12 May 2025

612.45

0.16%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Senores Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for Q4 and FY 2024-25 scheduled to be held on May 16, 2025 at 04:00 P.M. (IST).

pdf

Senores Pharmaceuticals Ltd.

09 May 2025

612.45

0.16%

Board Meeting

Senores Pharmaceuticals Ltd - 544319 - Board Meeting Intimation for Considering And Approving The Audited Standalone …

BSE India

Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 ,inter alia, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company, for the quarter and financial year ended March 31, 2025; and to transact any other business matters.

pdf

Senores Pharmaceuticals Ltd.

09 May 2025

612.45

0.16%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

BSE India

Senores Pharmaceuticals has informed the exchange regarding a press release dated May 09, 2025, titled "Senores Pharmaceuticals acquires ANDA for Tramadol Tablets from APDM Pharmaceuticals".

pdf

Senores Pharmaceuticals Ltd.

05 May 2025

612.45

0.16%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Senores Pharmaceuticals Limited has informed the Exchange regarding Media Release-"Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25,50,100 and 200 mg tablets"

pdf

Senores Pharmaceuticals Ltd.

02 May 2025

612.45

0.16%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Announcement Under Regulation 30 Of The Securities And Exchange Board …

BSE India

Senores Pharmaceuticals Limited has informed the Exchange regarding Intimation under Regulation 30 of Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulations, 2015.

pdf

Senores Pharmaceuticals Ltd.

23 Apr 2025

612.45

0.16%

Corp. Note

Senores Pharmaceuticals Ltd - 544319 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySenores Pharmaceuticals Ltd 2CIN NO.L24290GJ2017PLC100263 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 84.31 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Vinay Kumar Mishra Designation: Company Secretary and Compliance Officer EmailId: cs@senorespharma.com Name of the Chief Financial Officer: Deval Rajnikant Shah Designation: Chief Financial Officer and Whole Time Director EmailId: dshah@senorespharma.com Date: 23/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

RESEARCH REPORTS

SEE REPORTS >

pdf